Bibliography
- Freedberg I, Eisen A, Wolff K, et al. Fitzpatrick's Dermatology in General Medicine. McGraw-Hill, Columbus, Ohio; 1999
- Gladman DD, Stafford-Brady F, Chang CH, et al. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990;17:809-12
- McHugh NJ, Balakrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis. Rheumatology 2003;42:77-83
- Wong K, Gladman DD, Husted J, et al. Mortality studies in psoriatic arthritis. Results from a single clinic. I. Causes and risk of death. Arthritis Rheum 1997;40:1868-72
- Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998;41:1103-10
- Ettehadi P, Greaves WM, Wallach D, et al. Elevated tumor necrosis factor-α (TNF-α) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994;96:146-51
- Bonifati C, Ameglio F. Cytokines in psoriasis. Int J Dermatol 1999;38:241-51
- Yamauchi PS, Gindi V, Lowe NJ. The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety. Dermatol Clin 2004;22:449-59
- Bonifati C, Carducci M, Cordial Fei P, et al. Correlated increases of tumor necrosis factor-α, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients – relationships with disease activity. Clin Exp Dermatol 1994;19:383-7
- Mussi A, Bonifati C, Carducci M, et al. Serum TNF-α levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents 1997;11:115-8
- Partsch G, Steiner G, Leeb BF, et al. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997;24:518-23
- Cooper WO, Fava RA, Gates CA, et al. Acceleration of onset of collagen-induced arthritis by intra-articular injection of tumour necrosis factor or transforming growth factor-beta. Clin Exp Immunol 1992;89:244-50
- Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992;89:9784-8
- Goldring SR. Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology (Oxford) 2003;42:11-6
- Tsuboi M, Kawakami A, Nakashima T, et al. Tumor necrosis factor-α and interleukin-1β increase the Fas-mediated apoptosis of human osteoblasts. J Lab Clin Med 1999;134:222-31
- Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602
- Jones G, Crotty M, Brooks P. Interventions for psoriatic arthritis. Cochrane Database Syst Rev 2000;(3):CD000212
- Mease P, Goffe BS. Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol 2005;52:1-19
- Chandran V, Schentag CT, Gladman DD. Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. J Rheumatol 2007; published online 15 December 2007
- Enbrel (etanercept) prescribing information. Immunex Corporation, Thousand Oaks, CA, USA; 91320-1799
- Korth-Bradley JM, Rubin AS, Hanna RK, et al. The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother 2000;34:161-4
- Lebsack ME, Hanna RK, Lange MA, et al. Absolute bioavailability of TNF receptor fusion protein following subcutaneous injection in healthy volunteers. Pharmacotherapy 1997;17:1118-9
- Henter JI, Karlen J, Calming U, et al. Successful treatment of Langerhans'-cell histiocytosis with etanercept. N Engl J Med 2001;345:1577-8
- Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 2000;356:385-90
- Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis. Arthritis Rheum 2004;50:2264-72
- Gottleib AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139:1627-32
- Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis. Arthritis Rheum 2004;50:2264-72
- Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-22
- Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304-12
- Sacher C, Rubbert A, König C, et al. Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor α antagonist etanercept. J Am Acad Dermatol 2002;46:113-5
- Berookhim B, Fischer HD, Weinberg JM. Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor α antagonist etanercept. Cutis 2004;74:245-7
- Lin M, Hsu C, Lee JY. Successful treatment of recalcitrant pemphigus vulgaris and pemphigus vegetans with etanercept and carbon dioxide laser. Arch Dermatol 2005;141:680-2
- Henter JI, Karlen J, Calming U, et al. Successful treatment of Langerhans'-cell histiocytosis with etanercept. N Engl J Med 2001;345:1577-8
- Wagner AD, Andresen J, Jendro MC, et al. Sustained response to tumor necrosis factor α-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum 2002;46:1965-8
- Takada K, Aksentijevich I, Mahadevan V, et al. Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 2003;48:2645-51
- Arbach O, Gross WL, Gause A. Treatment of refractory Churg-Strauss-syndrome by TNF-α blockade. Immunobiology 2002;206:496-501
- Cortis E, De Benedetti F, Insalaco A, et al. Abnormal production of the tumor necrosis factor inhibitor etanercept and clinical efficacy of tumor in a patient with PAPA syndrome. J Pediatr 2004;145:851-5
- Kovach BT, Calamia KT, Walsh JS, Ginsburg WW. Treatment of multicentric reticulohistiocytosis with etanercept. Arch Dermatol 2004;140:919-21
- Pasternack FR, Fox LP, Engler DE. Silicone granulomas treated with etanercept. Arch Dermatol 2005;141:13-5
- Smith KJ, Skelton H. Common variable immunodeficiency treated with a recombinant human IgG, tumour necrosis factor-α receptor fusion protein. Br J Dermatol 2001;144:597-600
- Robinson ND, Guitart J. Recalcitrant, recurrent apthous stomatitis treated with etanercept. Arch Dermatol 2003;139:1259-62
- McGowan JW, Johnson CA, Lynn A. Treatment of pyoderma gangrenosum with etanercept. J Drugs Dermatol 2004;3:441-4
- Fautrel B, Foltz V, Frances C, et al. Regression of subacute lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha-blocking agent: comment on the article by Pisetsky and the letter from Aringer, et al. Arthritis Rheum 2002;46:1408-9
- Sfikakis PP. Behçet's disease: a new target for anti-tumor necrosis factor treatment. Ann Rheum Dis 2002;61:51-3
- Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. J Rheumatol 2005;32:98-105
- Stambe C, Wicks IP. TNF-α and response of treatment-resistant adult-onset Still's disease to thalidomide. Lancet 1998;352:544-5
- Husni ME, Maier AL, Mease PJ, et al. Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum 2002;46:1171-6
- Fautrel B, Sibilia J, Mariette X, Combe B. Tumor necrosis factor α blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann Rheum Dis 2005;64:262-6
- Tsimberidou AM, Giles FJ, Duvic M, Kurzrock R. Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas. J Am Acad Dermatol 2004;51:200-4
- Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and stage III progressive pulmonary sarcoidosis. Chest 2003;124:177-85
- Khanna D, Liebling MR, Louie JS. Etanercept ameliorates sarcoidosis arthritis and skin disease. J Rheumatol 2003;30:1864-7
- Ellman MH, MacDonald PA, Hayes FA. Etanercept as treatment for diffuse scleroderma: a pilot study [abstract]. Arthritis Rheum 2000;43:S392
- Lam GK, Hummers LK, Woods A, Wigley FM. Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol 2007;34:1636-7
- Penas PF, Fernandez-Herrera J, Garcia-Diez A. Dermatologic treatment of cutaneous graft versus host disease. Am J Clin Dermatol 2004;5:403-16
- Hattori K, Hirano T, Miyajima H, et al. Differential effects of anti-fas ligand and anti-tumor necrosis factor α antibodies on acute graft-versus-host-disease pathologies. Blood 1998;91:4051-5
- Chiang KY, Abhyankar S, Bridges K, et al. Recombinant human tumor necrosis factor receptor fusion protein as complimentary treatment for chronic graft-versus-host disease. Transplantation 2002;73:665-7
- Kamarashev J, Lor P, Forster A, et al. Generalized pustular psoriasis induced by cyclosporine a withdrawal responding to the tumor necrosis factor alpha inhibitor etanercept. Dermatology 2002;205:213-6
- Pereira TM, Vieira AP, Fernandes JC, et al. Anti-TNF-α therapy in childhood pustular psoriasis. Dermatology 2006;213:350-2
- Ricotti C, Kerdel FA. Subacute annular generalized pustular psoriasis treated with etanercept and cyclosporine combination. J Drugs Dermatol 2007;6:738-40
- Weinberg JM. Successful treatment of recalcitrant palmoplantar psoriasis with etanercept. Cutis 2003;72:396-8
- Lebwohl M. New developments in the treatment of psoriasis. Arch Dermatol 2002;138:686-8
- Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001;345:1098-104
- Bresnihan B, Cunnane G. Infection complications associated with the use of biologic agents. Rheum Dis Clin North Am 2003;29:185-202
- Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003;3:148-55
- Hamilton CD. Infectious complications of treatment with biologic agents. Curr Opin Rheumatol 2004;16:393-8
- Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85
- Corona R, Bigby M. What are the risks of serious infections and malignancies for patients treated with anti-tumor necrosis factor antibodies? Arch Dermatol 2007;143:405-6
- Shoor S. Review: anti-tumor necrosis factor antibody therapy for rheumatoid arthritis increases risk for serious infection and malignancy. ACP J Club 2006;145:65
- Callegari PE, Schaible TF, Boscia JA. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. JAMA 2006;296:2202
- Costenbader KH, Glass R, Cui J, Shadick N. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. JAMA 2006;296:2201
- Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37
- Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007;56:2886-95
- Wolfe F. Inflammatory activity, but not methotrexate or prednisone use predicts non-Hodgkin's lymphoma in rheumatoid arthritis: a 25-year study of 1,767 RA patients [abstract]. Arthritis Rheum 1998;41:S188
- Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46:3151-8
- Adams AE, Zwicker J, Curiel C, et al. Aggressive cutaneous T-cell lymphomas after TNFα blockade. J Am Acad Dermatol 2004;51:660-2
- Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007;56:1433-9
- Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9
- Kwon HJ, Cote TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003;138:807-11
- Haraoui B, Keystone E. Musculoskeletal manifestations and autoimmune diseases related to new biologic agents. Curr Opin Rheumatol 2006;18:96-100
- Debandt M, Vittecoq O, Descamps V, et al. Anti-TNF-α-induced systemic lupus syndrome. Clin Rheumatol 2003;22:56-61
- Watts RA. Musculoskeletal and systemic reactions to biological therapeutic agents. Curr Opin Rheumatol 2000;12:49-52
- Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9
- Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9
- Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy [letter]. Lancet 2002;359:579-80
- Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007;86:242-51
- Grinblat B, Scheinberg M. The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review. Semin Arthritis Rheum 2007;37:251-5
- www.enbrel.com [Accessed 15 November 2007]